Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 821

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 821
---
. H.Agreement with Pluri Inc. On July 17, 2024, the Company entered into a collaboration agreement with Pluri Inc. (Nasdaq: PLUR) (hereinafter, “Pluri”) for the clinical manufacturing (outsourced) of the Company’s products (hereinafter, the “Pluri Agreement”) at Pluri’s manufacturing facility in accordance with the Company’s strategic plan. The signing of the Pluri Agreement to manufacture the Company’s products constitutes a milestone in the development of the ASTRORX ®product, as part of the Company’s preparation for a multi -sitePhase IIA clinical trial (Phase A2), as well as in the development of the ISLETRX product in support of the Pre -INDsubmission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment within the framework of the aforementioned collaboration and as preparation for the submission of an IND application in the future. In accordance with the agreement, the Company will grant Pluri the right to use the knowledge developed by the Company for the benefit of Pluri’s production of the Company’s products, with the first phase lasting up to 12 months, in consideration of approximately USD $70,000 to be paid in cash or through issuance of Company securities, as to be agreed upon by the parties. I.On November 5, 2024, following approval by the Company’s Board of Directors, the Company entered into a definitive and binding merger agreement with the Swiss biopharmaceutical company NLS, whose shares are traded in the United States on the Nasdaq Stock Exchange under the symbol “NLSP”, which develops innovative treatments for rare and complex disorders of the central nervous system, and which was approved by the General Shareholders Meeting on January 30, 2025. Upon the closing of the transaction and subject to the cash balances of NLS and the Company, upon that date, the current shareholders of the Company will hold up to 85% of the issued and paid -upshare capital of NLS following the merger (hereinafter, the “Merged Company”), and the shares of the Merged Company will be traded on Nasdaq. The closing of the merger transaction is subject to fulfillment of conditions precedent. The agreement stipulates a number of conditions precedent related, among others, to actions that NLS is required to take prior to the closing of the merger transaction, including regarding the arrangement of the continued trading of its shares on Nasdaq and its compliance with the threshold conditions required